NICE is unable to make a recommendation about the use in the NHS of vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment. This is because Pfizer has confirmed that it does not intend to make an evidence submission for the appraisal at this time, as they are still evaluating their plans for the technology in this indication in the UK.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6360
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 11 September 2025 | Suspended. NICE is unable to make a recommendation about the use in the NHS of vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment. This is because Pfizer has confirmed that it does not intend to make an evidence submission for the appraisal at this time, as they are still evaluating their plans for the technology in this indication in the UK. |
| 05 July 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early July 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-September 2025. |
| 05 March 2024 | In progress. Topic in progress. |
| 05 September 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual